Cue Biopharma Announces $30 Million Private Placement

Cue Biopharma (NASDAQ: CUE) announced a private placement expected to raise approximately $30 million in gross proceeds via pre-funded warrants and accompanying warrants.

Rhea-AI Summary

Cue Biopharma (NASDAQ: CUE) announced a private placement expected to raise approximately $30 million in gross proceeds via pre-funded warrants and accompanying warrants. The PIPE is expected to close on or about May 4, 2026, subject to customary conditions and stockholder approval.

Proceeds are intended to advance the clinical pipeline, including acquiring and developing Ascendant-221, and for working capital and general corporate purposes. Newbridge Securities is placement agent; resale registration will be filed with the SEC.

Positive

• Gross proceeds of approximately $30 million to fund operations and pipeline
• Transaction structured with pre-funded warrants enabling near-term capital commitment
• Proceeds earmarked to acquire and develop Ascendant-221

Negative

• Up to 4,090,908 shares issuable on exercise could dilute existing shareholders
• PIPE requires stockholder approval before pre-funded warrants become exercisable
• Warrants expire on the fifth anniversary of closing, limiting long-term conversion timing

Argus May 1 session

+106.38% close to close Open Argus

Details

News Market Reaction – CUE

In the May 1 session, CUE gained 106.38%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +106.4% in the session following this news. A strong positive reaction aligns with ...

Analysis

The stock surged +106.4% in the session following this news. A strong positive reaction aligns with recent enthusiasm around CUE’s pipeline and collaborations, but the $30 million PIPE and existing $300,000,000 S-3 shelf underscore ongoing financing needs. Past events, such as the reverse split and going-concern language, highlighted balance-sheet pressure. Investors weighing the move would have needed to consider potential dilution from pre-funded warrants, common warrants, and future shelf usage when evaluating sustainability.

Key Figures

PIPE gross proceeds: $30 million Pre-funded warrants: 2,727,272 warrants Common warrants: 1,363,636 warrants +5 more

PIPE gross proceeds

$30 million

Private placement gross proceeds before fees and expenses

Pre-funded warrants

2,727,272 warrants

Aggregate pre-funded warrants to purchase common stock in PIPE

Common warrants

1,363,636 warrants

Accompanying common stock warrants (or pre-funded) in PIPE

Unit price

$11.00

Effective price per pre-funded warrant plus accompanying warrant

Pre-funded exercise price

$0.001 per share

Exercise price of pre-funded warrants

Warrant exercise price

$11.00 per share

Exercise price of common stock warrants

Warrant term

5 years

Warrants expire on fifth anniversary of PIPE closing

Shelf registration size

$300,000,000

Maximum aggregate amount registered on S-3 shelf

Historical Context

5 past events · Latest: Apr 22

5 events

1. Apr 22

   Reverse stock split

   24h Move

   -6.0%

   1-for-30 reverse split to regain Nasdaq bid price compliance.

2. Apr 15

   Preclinical data

   24h Move

   +65.4%

   New preclinical data on lead autoimmune candidate CUE-401 at IMMUNOLOGY2026.

3. Apr 08

   Milestone payment

   24h Move

   +45.5%

   $7.5M preclinical milestone from Boehringer Ingelheim collaboration for CUE-501.

4. Mar 27

   CEO transition

   24h Move

   -5.6%

   Interim CEO appointment and leadership change amid efforts to advance CUE-401.

5. Mar 26

   R&D day event

   24h Move

   -5.0%

   Announcement of virtual R&D Day focusing on CUE-401 research and Q&A.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

private placement, pre-funded warrants, warrants, accredited investors, +3 more

7 terms

private placement financial

"entered into a securities purchase agreement with certain accredited investors for a private placement"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

pre-funded warrants financial

"agreed to sell pre-funded warrants (“Pre-Funded Warrants”) to purchase an aggregate of up to 2,727,272 shares"

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

warrants financial

"accompanying common stock warrants (“Warrants”) to purchase an aggregate of up to 1,363,636 shares"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

View in glossary

accredited investors regulatory

"entered into a securities purchase agreement with certain accredited investors for a private placement"

Accredited investors are individuals or entities considered to have enough financial knowledge and resources to understand and handle more complex and risky investments. They are often allowed to participate in private investment opportunities that are not available to the general public, similar to how experienced players might access exclusive clubs or events. This status helps ensure that investors can manage potential risks and rewards appropriately.

registration statement regulatory

"Cue Biopharma has agreed to file a registration statement with the Securities and Exchange Commission"

A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

resale registration statement regulatory

"Any offering of the securities under the resale registration statement will only be made by means of a prospectus."

A resale registration statement is a document filed with regulators that allows existing shareholders to sell their shares to the public. It provides the necessary legal approval and information for these shares to be resold on the market, helping to increase the availability of shares for trading. For investors, it signals that shares held by current owners can be offered for sale, potentially affecting share prices and market liquidity.

placement agent financial

"Newbridge Securities Corporation is acting as placement agent for the PIPE financing."

A placement agent is a professional or firm that helps organizations raise money from investors, such as individuals, institutions, or funds. They act like matchmakers, connecting those seeking investments with the right investors and guiding the process to ensure successful funding. For investors, they can provide access to exclusive opportunities and help navigate complex fundraising efforts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, announced today that it has entered into a securities purchase agreement with certain accredited investors for a private placement (the “PIPE financing”) for gross proceeds of approximately $30 million to Cue Biopharma, before placement agent fees and offering expenses. The PIPE financing is expected to close on or about May 4, 2026, subject to the satisfaction of customary closing conditions.

Newbridge Securities Corporation is acting as placement agent for the PIPE financing.

In the PIPE financing, Cue Biopharma agreed to sell pre-funded warrants (“Pre-Funded Warrants”) to purchase an aggregate of up to 2,727,272 shares of common stock and accompanying common stock warrants (“Warrants”) to purchase an aggregate of up to 1,363,636 shares of common stock (or, in certain circumstances, Pre-Funded Warrants) at an effective price of $11.00 per Pre-Funded Warrant and accompanying Warrant. The exercise price of the Pre-Funded Warrants is $0.001 per share. The exercise price of the Warrants is $11.00 per share.

The Pre-Funded Warrants are exercisable at any time following receipt of approval by the Company’s stockholders at an upcoming special meeting of the Company’s stockholders (“Stockholder Approval”) and will not expire. The Warrants are exercisable following receipt of Stockholder Approval and will expire on the fifth anniversary of the closing of the PIPE financing.

Net proceeds from the PIPE financing are expected to be used to advance the Company’s clinical pipeline, including acquiring and developing Ascendant-221, working capital and other general corporate purposes.

The securities to be sold in the PIPE financing have not been registered under the Securities Act of 1933, as amended (“Securities Act”), or any state or other applicable jurisdiction’s securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws. Cue Biopharma has agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) registering the resale of the shares of common stock issuable upon the exercise of the Pre-Funded Warrants and Warrants issued in the PIPE financing.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer, solicitation or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offering of the securities under the resale registration statement will only be made by means of a prospectus.

About Cue Biopharma
Cue Biopharma (Nasdaq: CUE) is a clinical stage therapeutics company focused on advancing a portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its lead asset is a novel anti-IgE antibody with a dual-mechanism of action, currently in Phase 2 development for allergic diseases. In addition, Cue developed the Immuno-STAT^® platform which selectively targets disease-specific T cells in vivo without broad immune modulation. Its lead autoimmune candidate, CUE-401, is advancing towards Phase 1 and was designed to regulate inflammation and drive Treg-mediated tolerance. Cue is led by an experienced management team with deep expertise in identifying, acquiring, and advancing promising drug candidates.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the company’s statements about the expected closing of the PIPE financing; the company’s anticipated use of proceeds from the PIPE financing; whether the conditions for the closing of the PIPE financing will be satisfied; expectations with respect to obtaining the Stockholder Approval; and the company’s business strategies, plans and prospects. Forward-looking statements, which are based on certain assumptions and describe the company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Cue Biopharma may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on its forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Cue Biopharma makes as a result of various risks and uncertainties, including, among others, risks related to the satisfaction of customary closing conditions related to the PIPE financing and the impact of general economic, industry or political conditions in the United States or internationally and the other risks and uncertainties described in the Risk Factors sections of the company’s most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Reports on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor and Media Contact
Marie Campinell
Agnes Lee

ir@cuebio.com
Cue Biopharma, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much capital is Cue Biopharma (CUE) raising in the April 30, 2026 PIPE financing?

Cue Biopharma is raising approximately $30 million gross in the PIPE financing. According to the company, that amount is before placement agent fees and offering expenses and expected to close around May 4, 2026.

What securities is Cue Biopharma (CUE) selling in the private placement and at what prices?

The company is selling pre-funded warrants and accompanying warrants at an effective $11.00 price per unit. According to the company, pre-funded warrant exercise price is $0.001 and warrant exercise price is $11.00 per share.

How many shares could be issued if all Cue Biopharma (CUE) PIPE instruments are exercised?

If fully exercised, up to 4,090,908 shares could be issued (2,727,272 from pre-funded warrants and 1,363,636 from warrants). According to the company, that is the aggregate maximum share issuance in the PIPE.

What conditions must Cue Biopharma (CUE) meet before pre-funded warrants become exercisable?

Pre-funded warrants are exercisable only after the company obtains stockholder approval at a special meeting. According to the company, the exercisability is contingent on that stockholder approval.

How will Cue Biopharma (CUE) use the net proceeds from the PIPE financing?

Net proceeds will be used to advance the clinical pipeline, acquire and develop Ascendant-221, and for working capital and general corporate purposes. According to the company, these are the stated primary uses of funds.